Data from Pharmawand - Curated by EPG Health - Date added 07 June 2018

The National Institute for Health and Care Excellence has published draft guidelines rejecting the use of Zytiga (abiraterone acetate), from Janssen, plus androgen deprivation therapy and prednisone/prednisolone as a first-line treatment for patients with high-risk hormone-sensitive metastatic prostate cancer for use in the NHS. NICE noted that the cost of the drug did not fit in with patient's treatment and added that the estimate of the effectiveness of Zytiga with ADT versus best available treatment has not been fully explored.

Zytiga is approved for use by the NHS prior to chemotherapy but only after patients have received standard hormone therapy. In 2017 European regulators approved the use of the therapy as a first-line treatment for advanced prostate cancer, alongside hormone therapy. Zytiga was tested in the multinational, Phase III LATITUDE study demonstrated a significant improvement in overall survival (OS) and significantly prolonged radiographic progression-free survival (rPFS) in patients with high-risk metastatic hormone-naïve prostate cancer (mHNPC) compared to placebo plus ADT.


You will need to login, to leave a comment. is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Fluid Management

Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

+ 2 more

CDK 4/6 inhibitors in metastatic breast cancer

CDK 4/6 inhibitors in metastatic breast cancer

The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.

Load more

Related Content